NICE 'yes' for Gilead's Zydelig, a new class of drug for leukemia

24 September 2015
2019_biotech_test_vial_discovery_big

The UK medicines cost watchdog the National Institute for Health can Care Excellence (NICE) today issued final draft guidance recommending that US biotech giant Gilead Sciences’ (Nasdaq: GILD) Zydelig (idelalisib) should be made available on the National Health Service in England and Wales for some adults with chronic lymphocytic leukemia (CLL).

The NICE has recommended idelalisib, when given with another cancer treatment rituximab, for adults with CLL who have a specific genetic change and have not received any other treatment or for all adults with CLL if their cancer has come back less than 24 months after previous treatment. Idelalisib is the first of a new class of drug that work by blocking the signals which help cancerous cells multiply and survive.

Decision follows new economic analysts and price discount

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology